Prior Authorization Request Form for Cymbalta (duloxetine) 5671



To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) TRICARE pharmacy program (TPHARM). Express Scripts is the TPHARM contractor for DoD.							
MAIL ORDER and RETAIL		The provider may call: 1-866-684-4488 or the completed form may be faxed to: 1-866-684-4477 The patient may attach the completed form to the prescription and mail it to: Express Scripts, P.O. Box 52150, Phoenix, AZ 85072-9954 or email the form only to: TPharmPA@express-scripts.com					
Prior authorization criteria and a copy of this form are available at: http://pec.ha.osd.mil/forms_criteria.php. This prior authorization has no expiration date.							
1 F	Please complete patient and physician information (please print): Patient Name: Physician Name:						
F	Address:		Address:				
	Sponsor ID # Phone #: Date of Birth: Secure Fax #:						
Step			ical assessment:				
	1. What is the diagnosis?		 Depression, generalized anxiety disorder (GAD), or other psychiatric condition 	Proceed to Step 3 on following page			
			□ Neuropathic pain□ Fibromyalgia	Proceed to Step 4 on following page			
_			□ Other (specify):	Coverage not approved			

Prior Authorization Request Form for Cymbalta (duloxetine) 5572



Step	Depression, generalized anxiety disorder (GAD), or other psychiatric condition				
3	1. The Step 1 agents are: 1) venlafaxine [Effexor, Effexor XR]; 2) SSRIs [selective serotonin reuptake inhibitors, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline]; 3) nefazodone, trazodone; 4) bupropion HCL [Wellbutrin]; 5) mirtazapine [Remeron]; 6) TCAs [tricyclic antidepressants: amitriptyline (Elavil), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil)]; and, 7) MAO inhibitors [monoamine oxidase inhibitors: Emsam, Marplan, Nardil, Parnate].	Proceed to question 2			
	2. Are ALL of the Step 1 agents listed above contraindicated in this patient?	Yes Sign and date below	No Proceed to Question 3		
	3. Has the patient previously responded to Cymbalta and changing to a Step 1 agent would incur unacceptable risk?	Yes Sign and date below	No Proceed to Question 4		
	4. Has the patient tried one of the Step 1 agents and experienced adverse effects?	Yes Document agent(s) in 6	No Proceed to Question 5		
	5. Has the patient had an adequate therapeutic trial with one of the Step 1 agents and the use resulted in therapeutic failure?	Yes Document agent(s) in 6	No Coverage not approved		
	6. DOCUMENT the Step 1 agents(s) that has been tried, then sign and	d date below:			
	Neuropathic pain, Fibromyalgia				
Step 4	1. The Step 1 agents are: 1) venlafaxine [Effexor, Effexor XR]; 2) gabapentin [Neurontin]; 3) TCAs [tricyclic antidepressants: amitriptyline (Elavil), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil)]; and, 4) cyclobenzaprine.	Proceed to	question 2		
	2. Are ALL of the Step 1 agents listed above contraindicated in this patient?	Yes Sign and date below	No Proceed to Question 3		
	Has the patient previously responded to Cymbalta and changing to a Step 1 agent would incur unacceptable risk?	Yes Sign and date below	No Proceed to Question 4		
	Has the patient tried one of the Step 1 agents and experienced adverse effects?	Yes Document agent(s) in 6	No Proceed to Question 5		
	5. Has the patient had an adequate therapeutic trial with one of the Step 1 agents and the use resulted in therapeutic failure?	Yes Document agent(s) in 6	No Coverage not approved		
	6. DOCUMENT the Step 1 agents(s) that has been tried, then sign and	d date below:			
Step 5	I certify the above is true to the best of my knowle Please sign and date:	edge.			
	Prescriber signature	Date Date			
			[18 April 2012]		